The Swiss pharmaceutical company wants to speed up the development of its drugs against diabetes and obesity. Roche CEO Thomas Schinecker told the "Financial Times" that the company's first anti-obesity drugs would come onto the market "much faster than expected" - possibly by 2028. This booming market is currently dominated by the American company Eli Lilly and the Danish company Novo Nordisk. In mid-July, Roche once again published positive study data on a potential weight loss drug. This involved the candidate CT-996, which is taken once a day to treat type 2 diabetes and obesity. The drug comes from the portfolio of the American company Carmot, which Roche acquired in December for around $3 billion. Like several anti-obesity drugs in development, CT-996 belongs to the new class of lipid-lowering drugs, the GLP-1 drugs. It achieved significant results in two sub-studies of an ongoing multi-part Phase I clinical trial. Only shortly before this, Roche had published data on its ...
